Abstract
Purpose of review. Lung transplantation activity continues to be limited by the availability of timely quality donor lungs. It is apparent though that progress has been made. The steady evolution of clinical practice, combined with painstaking scientific discovery and innovation are described. Recent findings. There have been successful studies reporting innovations in the wider use and broader consideration of donation after circulatory death donor lungs, including an increasing number of transplants from each of the controlled, uncontrolled and medically assisted dying donor descriptive categories. Donors beyond age 70 years are providing better than expected long-term outcomes. Hepatitis C PCR positive donor lungs can be safely used if treated postoperatively with appropriate antivirals. Donor lung perfusion at a constant 10 degrees appears capable of significantly improving donor logistics and ex-vivo lung perfusion offers the potential of an ever-increasing number of novel donor management roles. Bioartificial and xenografts remain distant possibilities only at present. Summary Donor lungs have proved to be surprisingly robust and combined with clinical, scientific and engineering innovations, the realizable lung donor pool is proving to be larger than previously thought.
| Original language | English |
|---|---|
| Pages (from-to) | 398-404 |
| Number of pages | 7 |
| Journal | Current Opinion in Pulmonary Medicine |
| Volume | 30 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- donation after circulatory death
- ex vivo lung perfusion
- lung transplantation
- organ donor management
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver